2019
DOI: 10.4236/abcr.2019.83009
|View full text |Cite
|
Sign up to set email alerts
|

Serum Y-Box Binding Protein 1 (YBX-1) and Interleukin 6 (IL-6) Are Associated with Metastasis in Breast Cancer Patients

Abstract: Objectives: The aim of this study was to assess the levels of Y-box binding protein 1 (YBX-1) and interleukin 6 (IL-6) in the sera of metastatic and non-metastatic breast cancer patients (BC), investigate their clinicopathological significance and to analyze their potential use as biomarkers of breast cancer metastasis. Methods: The study included ninety subjects sub-grouped equally into metastatic BC, non-metastatic BC and healthy volunteers. Serum YBX-1 and IL-6 were quantified using ELISA technique while CA… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 38 publications
(38 reference statements)
1
1
0
Order By: Relevance
“…From the obtained results ibuprofen inhibits COX-1 when it is used for a long duration after 28 days of exposure to a high dose of ibuprofen (40 mg/kg) used in this study, which is in line with previous studies. Also, high chronic doses of ASA play a role in the inhibition of COX-1 and these results agree with previous studies (Abd-Elaziz et al, 2019).…”
Section: Discussionsupporting
confidence: 93%
“…From the obtained results ibuprofen inhibits COX-1 when it is used for a long duration after 28 days of exposure to a high dose of ibuprofen (40 mg/kg) used in this study, which is in line with previous studies. Also, high chronic doses of ASA play a role in the inhibition of COX-1 and these results agree with previous studies (Abd-Elaziz et al, 2019).…”
Section: Discussionsupporting
confidence: 93%
“…IL-6 is upregulated in several malignancies, including melanoma, and higher levels are associated with progression of disease, worse clinical outcomes, and therapeutic resistance [ 6 ]. Increase IL-6 was associated with worse prognosis in a number of cancers [ 7 , 8 ], including pancreatic [ 9 ], esophageal [ 10 ], melanoma, head and neck squamous cell carcinoma [ 11 ], and colon [ 12 , 13 ]. Furthermore, people with cervical cancer are probably has lower chance of surviving than those whose tumors contain low concentrations of IL-6 [ 14 ].…”
Section: Introductionmentioning
confidence: 99%